Charles W. Gorodetzky, MD, PhD
Consultant in Pharmaceutical Medicine, Kansas City, Missouri
Letter to the Editor
Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides
September 8, 2025
The authors reply to Ferré and Michaelides’ letter commenting on their recent study of long-term esmethadone treatment in MDD.